Biologics: A World Of Possibilities

Biologics: A World Of Possibilities

03.11.13 | By Preet Bilinski

Biologics are at the cutting-edge of research and changing our ideas about drug discovery and development. The mapping of the human genome coupled with a greater understanding of the molecular workings of disease, have improved our ability to treat diseases in new and innovative ways. Biologics are structurally different from most existing treatments and allow for precise targeting, changing the treatment options available for many diseases. In many cases biologics are the first treatment available for a disease or offer a different way to treat a given disease.

Impressive progress against many cancers have been made with biologics, and biologic medicines being researched today are looked to for advances against such diseases as Alzheimer's and Parkinson's. In the last decade alone, biologics have accounted for one third of annual approvals, according to PhRMA's New Drug Approval reports. We continue to build on the impressive progress to date with America's biopharmaceutical research companies using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, including

  • 338 for cancer that target several different types of solid tumors, leukemia and lymphoma.
  • 176 for a variety of infectious diseases, including 134 vaccines
  • 71 for autoimmune diseases, such as lupus, multiple sclerosis and rheumatoid arthritis.

Biologics remain a budding research field that holds tremendous promise for the treatment and prevention of numerous illnesses. They are extremely complex medications to produce and require several years of research and development before a product is approved for patient use. Despite the obstacles, U.S. biotechnology firms account for 80% of the world's research & development in biotechnology. Biologics hold great promise for the treatment and prevention of numerous illnesses, they hold a world of possibilities.

Learn more out the innovative potential medicines America's biopharmaceutical companies are working on today in our new Medicines in Development report on biologics.

More On PhRMA — powered by PhRMApedia


Cost in Context